The T-cell drug developer has launched with $20m from a seed round co-led by corporate venturing unit Novartis Venture Fund.
US-based T-cell therapy developer GentiBio closed a $20m seed round yesterday co-led by Novartis Venture Fund, the corporate venturing unit for pharmaceutical firm Novartis.
The round was co-led with healthcare-focused investment firm OrbiMed and investment manager RA Capital Management.
GentiBio is developing drugs intended to restore immune system function through regulatory T-cells engineered by the startup. The approach could lead to treatments for autoimmune, autoinflammatory, alloimmune and allergy-based diseases.
The company has licensed technology from Seattle Children’s Hospital and Benaroya…
